Imatinib, a tyrosine kinase inhibitor (TKI) of BCR-ABL, was the standard first-line therapy for chronic myeloid leukemia (CML) for almost 10 years. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.